StockData
Nuvation Bio Inc. logo

Nuvation Bio Inc. (NUVB) stock

NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.78−0.12 (-3.08%)

Close on Nov 18, 2026Market cap $1.33BP/E –Yield –

Nuvation Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Nuvation Bio's revenue for the twelve months ending Jun 30, 2026 was $169.90M, up 1083.6% year over year. For fiscal 2025 it was $62.90M, up 699.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$62.90M+699.0%
FY2024Dec 31, 2024$7.87M–
FY2023Dec 31, 2023$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$31.69M+555.6%
Q1 FY2026Mar 31, 2026$83.23M+2598.7%
Q4 FY2025Dec 31, 2025$41.87M+633.1%
Q3 FY2025Sep 30, 2025$13.12M+1704.7%
Q2 FY2025Jun 30, 2025$4.83M+236.8%
Q1 FY2025Mar 31, 2025$3.08M–
Q4 FY2024Dec 31, 2024$5.71M–
Q3 FY2024Sep 30, 2024$727.00K–
Q2 FY2024Jun 30, 2024$1.44M–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–

More Nuvation Bio figures

See a number that looks wrong?